James S. Burns is currently co-founder and Executive Chairman of Phenomics Health, a bioinformatics-based platform precision medicine company commercializing AI and machine learning-enabled genetic, epigenetic, multi-omics and health big data into novel pharmacological clinical treatment decision support products and disease-drug response network services across multiple drug categories. He served previously as Executive Chairman, President & CEO of Assurex Health, a precision medicine company focused on neuropsychiatric and pain disorders. Dr. Burns has over 35 years’ executive experience in the pharmaceutical, biotechnology, medical device, and diagnostic fields. He has covered translational research and commercialization of novel pharmaceuticals, stem cells, gene therapy, monoclonal antibodies, flow cytometry, DNA analysis, tissue transplantation, and neuropsychiatric pharmacogenomics. He has served in leadership roles as chairman, CEO, senior executive, company founder, and general management in businesses ranging from early-stage companies to large multinational corporations, venture capital, and private equity.
AI and Data Sciences Showcase:
Phenomics Health Inc.
Phenomics Health is a bioinformatics-based platform precision medicine company commercializing AI and machine learning-enabled genetic, epigenetic, multi-omics and health big data into novel pharmacological clinical decision support products and disease-drug response network services.
Resolving Previously Unrecognized Drug Mechanisms Of Action
Phenomics platform supports products and services based on non-coding variants of the human genome consisting of spatial, temporal, and mechanical regulatory mechanisms of gene regulation, transforming our understanding of regulatory genomics, transcriptional hierarchy, and nuclear structural dynamics.
The PMWC 2020 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.